Vivos (RDGL) Debt to Equity (2011 - 2023)

Vivos' (RDGL) quarterly Debt to Equity came in at $0.01 in Q3 2023, up 100.79% quarter-over-quarter from -$0.87 in Q3 2018.

Vivos (RDGL) Debt to Equity (2011 - 2023) Analysis & Trends

Vivos has disclosed Debt to Equity across 9 years of filings, most recently posting $0.01 for Q3 2023.

Debt to Equity for Q3 2023 came in at $0.01, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was $0.01 (changed N/A YoY), and the FY2016 annual result was -$0.15, up 50.7% from the prior year.
Debt to Equity came in at $0.01 for Q3 2023 at Vivos, up from -$0.87 in the prior quarter.
In the past five years, Debt to Equity ranged from a high of $0.01 in Q3 2023 to a low of $0.01 in Q3 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	0.65
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	0.64
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	0.57
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	0.42
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	0.06
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.71
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	0.95
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	0.27
10	Vivos	-	-	-3,105.00	-

Historic Data

Download Data

Date	Value
Sep 30, 2023	0.01
Sep 30, 2018	-0.87
Jun 30, 2018	-0.49
Mar 31, 2018	-0.01
Sep 30, 2017	-0.11
Jun 30, 2017	-0.03
Mar 31, 2017	-0.03
Dec 31, 2016	-0.15
Sep 30, 2016	-0.02
Jun 30, 2016	-0.07
Mar 31, 2016	-0.07
Dec 31, 2015	-0.30
Sep 30, 2015	-0.31
Jun 30, 2015	-0.01
Mar 31, 2015	-0.43
Dec 31, 2014	-0.22
Sep 30, 2014	-0.05
Jun 30, 2014	-0.22
Mar 31, 2014	-0.05
Dec 31, 2013	-0.04